Hui-Chi Gene Accelerates Growth in Precision Medicine and Digitalization: Unveils Multi-faceted Strategy Including FHIR Compliance
慧智五大成長引擎齊發精準醫療布局邁入收成期 - 自立晚報
Summary
At a corporate briefing, Hui-Chi Gene announced that it is developing five growth engines—including maternal-fetal medicine and cancer precision medicine—and focusing on areas like policy utilization, technology upgrades, international cooperation, screening, and digital transformation. Notably, the company is advancing the construction of clinical data exchange systems through FHIR compliance.
Details
Hui-Chi Gene is executing a multi-faceted strategy to secure long-term growth momentum, centering on maternal-fetal medicine and cancer precision medicine as its two core businesses. In reproductive medicine, it has upgraded PGT-A technology and expanded high-level screening services such as NIPS and WES through partnerships with Baylor Genetics in the US. For cancer precision medicine, capitalizing on the expansion of NGS testing by the National Health Insurance Administration (NHIA), the company is providing companion diagnostics (CDx) and precise drug testing for specific cancers like gynecological and breast cancer, maintaining high growth. Crucially, the company has completed FHIR (Fast Healthcare Interoperability Resources) validation. This includes participation in NGSD data collection drills with the NHIA and clinical data exchange verification with medical centers. This establishes a complete digital process—from structuring test results to data exchange and even NHIA claims submission—enhancing service efficiency and customer loyalty. These efforts are expected to strengthen the company's competitive edge.
Original content copyright by respective publishers